Management of Metastatic Prostate Cancer Biochemical Recurrence with Use of 18F-DCFPyL PET/CT
- 1 May 2022
- journal article
- editorial
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 303 (2) , 423-424
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry TrialRadiology, 2022
- 68Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based ChemotherapyJournal of Nuclear Medicine, 2021
- 68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional studyTranslational Oncology, 2021
- Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mLJournal of Nuclear Medicine, 2019
- Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate CancerRadiology, 2018
- Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate CancerEuropean Urology, 2016